Despite the dismal prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN), there have been no novel treatments in over 40 years. Identification of novel tumor antigens in SCCHN will facilitate the identification of potential novel treatment targets. Tumor antigens are proteins selectively expressed by tumor cells and recognized by the host immune system. Phage-displayed tumor antigens were enriched by biopanning with normal and then SCCHN-specific serum. Ninety-six phage clones were sequenced for identification, and 21 clones were validated using Luminex. One of these proteins, L23, a novel tumor antigen in SCCHN, was validated as an oncogene. L23 is upregulated in SCCHN compared with normal keratinocytes. Knockdown of L23 inhibited proliferation, invasion and cell survival. Overexpression of L23 had the reverse effect. Overexpression of L23 in non malignant cells led to transformation. Injection of SCCHN cells with knockdown of L23 in mice, induced tumors that were significantly smaller than control tumors. In conclusion, the immunomic screen yielded a panel of antigens specific to SCCHN; one of these proteins, L23, is a novel oncogene in SCCHN.
INTRODUCTION
Characterization of the genes that regulate growth, survival and invasion of head and neck cancer will identify potential novel treatment targets. Squamous cell carcinoma is a common cancer occurring in the head and neck, skin, esophagus, lung and cervix. Squamous cell carcinoma of the head and neck (SCCHN) is 1 of the 10 most common cancers globally, affecting B600 000 individuals. 1 In the US alone, oral cancer accounts for more deaths annually than cervical cancer, melanoma or lymphoma. 2 The 5-year survival rate of SCCHN is o50%, a prognosis that is poorer than breast cancer or melanoma. 3 Despite this dismal survival, there have been no novel therapeutic agents for SCCHN in over 40 years. This emphasizes the need for new biomarkers of SCCHN that will serve as potential therapeutic targets.
The immune response can be harnessed to identify novel tumor antigens in SCCHN. Tumor antigens are proteins that are selectively expressed by tumor cells and recognized by the host immune system. 4, 5 These antigens are secreted, expressed on the cell surface or are intracellular proteins that are released into the surrounding tissues when the tumor cells break down. 4 Characterization of the antibody response to these proteins can be utilized to identify novel tumor antigens. [6] [7] [8] [9] Phage display is an unbiased approach to identifying tumor antigens via the antibody response. Essentially, bacteriophage vectors are engineered so that the coding sequence for a peptide or protein is fused to the coding sequence of a phage capsid protein, expressed and displayed on the surface of the phage as a fusion protein. 10, 11 In contrast to other cloning strategies, phage display of peptides and proteins is amenable to affinity enrichment. 10, 12, 13 In a process known as biopanning, the phage particles displaying a tumor antigen are reacted with serum. The unbound phage particles are washed away and the bound particles are retrieved by disruption of the bond between the antibodies and the displayed phage protein. 10, 11 Epitopes are identified via microarray and sequencing. 11 In a novel discovery approach for SCCHN biomarkers, we used phage libraries constructed from multiple different cancers in conjunction with the immune response in SCCHN to retrieve a panel of SCCHN tumor antigens. Furthermore, we validated the oncogenic role of one of these antigens, L23, using tissues, cell lines and animal models of human SCCHN.
RESULTS
Phage libraries from multiple cancers were combined and enriched for SCCHN-specific tumor antigens using biopanning ( Figure 1 ). After 5 rounds of biopanning, 1152 clones were randomly selected for construction of an immunomic array. These arrays were used to screen 48 SCCHN and 34 control serum samples and yielded a prediction accuracy of 77% (Figure 1b) . The top 96 clones selected by regularized logistic regression, yielded the best performance based on their specificity and sensitivity as measured by the receiver-operating-characteristic curve. The specificity was 70.6% (95% confidence interval, 52.5-84.9), while sensitivity was 81.3% (95% confidence interval, 67.4-91.0). These clones were sequenced for identification. Twenty-one clones were further validated by the Luminex 200 system. The SCCHN serum used for biopanning was assayed for the antibodies of the 21 clones. This further validates that the antibodies are indeed present in the serum. The optimal cross-validated receiveroperating-characteristic curve showed an area under the curve of 0.72 ( Figure 1c ) with a sensitivity of 84% and specificity of 50% presenting a reasonable trade off resolution. These findings indicated the strong predictive potential of this signature.
Of the 96 clones sequenced, 6 were in-frame, 6 were identified by the 5 0 or 3 0 sequences and 18 were out-of-frame (Figure 2a ). The 6 in-frame clones identified were L23, NFATC2-IP, STYXL1, L12, FTH1 and SNX3/SDP3 (Figure 2b ). The remaining clones were unidentified proteins (Table 1) . None of these clones overlapped with those observed in the cancers from which the phage libraries were derived. The immunoreactivity of the six in-frame clones, when assessed across the 48 SCCHN and 34 control serum samples, shows strong reactivity in cancer compared with normal ( Figure 2c) . Expression of the six in-frame proteins was evaluated from the Oncomine database. It was observed that each of these proteins was significantly overexpressed in SCCHN compared with normal ( Figure 2d ). In a meta-analysis of published gene expression studies in SCCHN, 4/6 proteins had a significant increase in gene expression across all studies (Figure 2e ). L23 was selected for expression and validation studies based on its strong immunomic signature (Figure 2c) , the meta-analysis (Figures 2d and e), as well as limited published in vitro studies showing a correlation with cancer. [14] [15] [16] Ten SCCHN cell lines were evaluated for L23 transcript and protein. 7/10 cell lines contained significantly more transcript for L23 than normal keratinocytes (HOK) (Figure 3a ) and 9/10 cell lines exhibited a significant increase in protein expression (Figure 3b ). Immunoblot analysis of tissue lysates from SCCHN and matched (same patient) normal tissues showed that L23 is upregulated in 3/5 tumor samples relative to normal tissue (Figure 3c ). Imunohistochemical studies in tissue sections from SCCHN showed a significant increase in the proportion of SCCHN cells exhibiting L23 expression compared with normal epithelial cells (Figure 3d) . Expression in the normal tissue was restricted to the basal third of the epithelium, whereas SCCHN tissue expressed L23 throughout the tumor islands (Figure 3d ). No significant difference in the intensity of expression was observed between tumor and normal epithelium (not shown). To determine the effects of L23 overexpression on tumorigenic phenotypes, proliferation, survival and invasion assays were performed in two independent SCCHN cell lines. UM-SCC-22B and OSCC3, SCCHN cell lines with high endogenous L23 expression were subjected to small interfering RNA (siRNA)-mediated knockdown of L23 with two different siRNAs, si11 and si12. UM-SCC-22B showed 33% knockdown with si11 and 11% knockdown with si12 ( Figure 4a ). Forty-eight hours after Immunomic biomarkers in squamous cell carcinoma N Russo et al compared with those transfected with non target siRNA (Figure 4g, top panel) . This can be visualized in the TUNEL assay (Figure 4g, bottom panel) . Cells transfected with siL23 were also significantly less invasive than those transfected with non target siRNA (Figure 4h ). Data are representative of three replicates in three independent experiments.
In complementary studies, L23 was overexpressed in UM-SCC-11A, which has low endogenous L23 ( Figure 5 ). Following transfection, a mixed clonal population was selected with G418 and overexpression was confirmed by immunoblot analysis (Figure 5a ). Cells transfected with pcDNA-L23 had 263% higher expression of L23 than the pcDNA control. A significant increase in cell proliferation was observed at 48, 96 and 120 h after seeding (Figure 5b ). There was no significant difference in apoptosis between cells overexpressing L23 and control, demonstrated both by flow cytometry (Figure 5c , top panel) and TUNEL (Figure 5c , bottom panel). Cells overexpressing L23 were significantly more invasive than the pcDNA control (Figure 5d ). Data are representative of three replicates in three independent experiments.
In order to verify whether L23 is an oncogene, non transformed NIH 3T3 cells were transfected with L23 and pcDNA control. Overexpression of L23 in 3T3 cells was confirmed by immunoblot ( Figure 5e ). The 3T3 cells ovexpressing L23 formed significantly more foci than the control (Figure 5f ), consistent with a role for L23 as an oncogene. Data are representative of three independent experiments with three replicates in each experiment.
To determine if L23 promotes proliferation in vivo, UM-SCC-22B cells were transduced with shL23. Cells transduced with shL23 showed a 65% knockdown in L23 expression when compared with control ( Figure 6a ) and had significantly slower proliferation (Figure 7d) . shControl tissue has a significantly higher frequency of PCNA staining than shL23 (Figure 7e ), consistent with a higher rate of proliferation. TUNEL was also performed on the tissue to gauge apoptosis within the shControl and shL23 tumors. The percent of FITCpositive cells in the shL23 tumor was significantly higher than in the shControl tumor (Figure 7f) . Together, our data show that L23 has a tumorigenic role in SCCHN.
DISCUSSION
In this study, we used the antibody response to SCCHN to identify novel tumor antigens. Using this approach, phage libraries from different cancers were combined for biopanning sera from SCCHN to develop an array ('immunomic array') for SCCHN. This array was used to screen additional SCCHN and control serum samples. The top 96 clones were sequenced and 6 of these were in-frame proteins. Twenty of these clones, including in-frame proteins, were also validated by the Luminex system. The Luminex system allows for the quantification of multiple proteins in one assay. One of the clones, identified by sequencing as the protein L23, was determined by in vitro and in vivo studies to promote tumor progression. This is the first functional investigation of the role of L23 in SCCHN.
Expression of a tumor biomarker or the relative level of the biomarker distinguishes normal from malignant states. Detection or quantification of the levels of tumor markers may facilitate diagnosis, staging, population screening, response to treatment or identification of metastatic or recurrent disease. 17 An important strategy in biomarker discovery was to compare gene expression profiles between normal and cancer tissue using DNA microarrays. For example, using laser capture microdissection of SCCHN in conjunction with DNA microarrays, Leethanakul et al. 18 showed reduced expression of differentiation markers such as cytokeratins and increased expression of mitogenic and angiogenic proteins Immunomic biomarkers in squamous cell carcinoma N Russo et al and metalloproteinases in SCCHN. These strategies detect transcriptional changes. However, as cell function and phenotype are determined by protein expression, differential protein expression is a preferred method to identify tumor biomarkers.
The humoral immune response of cancer patients can be utilized to isolate novel tumor antigens. [6] [7] [8] [9] In contrast to highthroughput approaches, such as serological analysis of recombinant complementary DNA (cDNA) expression libraries of human tumors with autologous serum (SEREX), which rely on a single-step screening technique, the sensitivity and selectivity are higher when the selection is performed through multiple, sequential enrichment steps, a major advantage of fusion phage-display technology. 19 In the phage-display approach, multiple rounds of biopanning enrich cancer-specific epitopes, thereby increasing the sensitivity and specificity of the phageligand complex. The epitope displayed on the surface of filamentous phages enriches antibody-binding ligands. 19 Chinnaiyan and Wang, 11 generated phage-displayed cDNA libraries derived from localized prostate cancer tissue and using the expressed epitopes, constructed an 'immunomic' array. The latter was used to compare the autoantibody signature in serum from prostate cancer and control subjects. Using this approach, tumor-specific peptides and corresponding antibodies selectively present in the serum of prostate cancer patients were identified.
In the current study, phage libraries generated from multiple cancers were used for biopanning SCCHN epitopes. Importantly, the multiplexed panel of clones was unique to SCCHN and did not overlap with the cancers from which the phage libraries were derived. This suggests that each cancer has its own unique signature.
L23 is a ribosomal protein that promotes nucleolar stressinduced p53 activation. 20 Nucleolar stress induces ribosomal proteins, L23, L5 and L11 to form a quadruple complex with MDM2. [21] [22] [23] [24] Sequestration of MDM2 in the nucleolus by the complex, promotes accumulation and activation of p53 with subsequent p53-mediated cell-cycle arrest and DNA repair. 24 However, p53 activation is detrimental if it has an oncogenic mutation. In B50-80% of SCCHN patients, p53 is mutated. [25] [26] [27] Therefore, an accumulation of L23 can lead to an accumulation of mutant p53, which could promote tumor growth and progression. It has been suggested that the ribosomal proteins, including L23, that bind to MDM2 serve as non oncogene addiction proteins that are required for cancer. 20 Before the current study, the role of L23 as an oncogene was not established in vivo. In gastric cancer cells, overexpression of L23 promotes resistance to the chemotherapeutic agents, cisplatin and 5-fluorouracil. 16 Another study showed that L23 promotes the growth rate of colon cancer cells via inhibition of Miz1.
14 L23 was found to be a metastasis related gene in a human lung adenocarcinoma cell line. 15 However, the limited in vitro studies did not establish an oncogenic role for L23.
Although L23 has not been previously investigated in SCCHN, it was identified by proteomic analysis as being upregulated in SCCHN relative to normal epithelium. 28 Future studies will focus on the mechanism by which L23 promotes tumorigenesis in SCCHN with particular focus on the MDM2-p53 pathway. It is unclear why overexpression of L23 did not impact apoptosis in UM-SCC-11A, whereas downregulation of L23 promoted apoptosis in UM-SCC-22B and OSCC3. This may be related to the signaling mechanism and factors such as the p53 status. Mechanistic studies will elucidate this possibility. Our studies showing the antigenicity of L23 in SCCHN and its role in potentiating proliferation, invasion and survival, suggest that L23 is a potential target for immunotherapy. In support of this suggestion, ribosomal proteins that are mutant or overexpressed in cancer are targeted by anti-cancer immune responses. 29 For example, mutant L9 and L11 in a murine fibrosarcoma are recognized by T-cells. 30, 31 Beck-Engeser et al. 32 suggested that in the absence of normal alleles, targeting L9 or L26 tumor antigens, would suppress tumor growth. Similar to our findings with L23, low expression of L10a is observed in normal cells, whereas it is overexpressed in head and neck and lung cancers. 33 Furthermore, L10a peptides induced cytotoxic-T-lymphocyte activity in peripheral blood mononucelear cells from cancer patients, suggesting the use of ribosomal peptides for immunotherapy in cancer patients. 33 In our study, L23 induced an antibody response in SCCHN patients. Ferris et al. 34 discussed how the antibody response to tumor antigens can stimulate the cellular immune response, including cytotoxic T-lymphocytes, that targets tumor antigens. Thus, given its ability to induce an antibody response, and the role of ribosomal proteins in inducing a cellular immune response, L23 may be a target for immunotherapy.
The immunomics approach can be used to develop a SCCHN signature to improve detection of SCCHN and monitor response to treatment. The poor prognosis of SCCHN is due to late detection, which occurs as a consequence of inadequate screening protocols. 35 Visual inspection of the oral cavity is the most common screening technique for oral cancer. 35 However, 450% of intraoral cancers develop as asymptomatic lesions in the posterior-lateral tongue, an area that is poorly visualized on routine clinical exam. [35] [36] [37] Even in the easily visualized anterior floor of mouth region where B35% of oral cancers occur, SCCHN may present as a red or white patch that is misinterpreted as inflammation or irritation. Furthermore, patients treated for SCCHN have a high risk for tumor recurrence. One way to improve the detection of SCCHN and to monitor response to treatment is to use an immunomics approach to develop a signature specific to SCCHN. This approach was successfully used to propose a diagnostic signature for prostate cancer.
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In the present study, we used a novel approach to identify unique tumor antigens for SCCHN. This immunomics approach can be used to develop a serum-based biomarker signature to monitor response to treatment or potentially for a diagnostic test in high-risk individuals.
MATERIALS AND METHODS Immunomics
Previously established phage libraries for prostate, lung, breast, esophagus and colon cancers 11, 38 were combined and used for biopanning with sera from 30 control patients or from 30 randomly selected SCCHN patients, using the T7Select System (Millipore, Billerica, MA, USA). The phage libraries were first incubated with control serum and non-specific epitopes were discarded. The remaining phages were incubated with SCCHN serum and enriched with pooled IgGs. The phages were then propagated in bacteria and isolated. After five cycles of biopanning, 1152 clones were randomly selected for construction of an immunomic array. These arrays were used to screen 48 SCCHN and 34 control serum samples. The immunomic microarrays were rinsed and blocked followed by incubation with human serum (normal or cancer) and mouse anti-T7 (phage) tag antibodies, followed by incubation with Cy3 labeled anti-mouse antibody and Cy5-labeled anti-human antibody. The slides were scanned and the ratio of Cy5 to Cy3 was calculated for each phage spot. The ratio of the T7 negative control was subtracted from the ratio for each spot. All available biomarkers were considered potential candidates for an optimal predictive signature of cancer. As the number of candidates is relatively high compared with the number of samples, regularization methods based on logistic regression were used. LASSO and Elastic Nets penalty were applied, and a full regularization path was computed. The choice of the optimal regularization parameter was done by maximizing the area under the receiver-operating-characteristic curve as a criterion. Ten-fold cross validation was used to correct for overoptimistic model building bias. An average over cross-validation runs are reported as the final optimal area under the curve characterizing the predicted performance of the biomarker signature in future observations. LASSO penalty was preferred for its ability to drop non-essential biomarkers from the signature by explicitly assigning them zero weights. The 96 phage-displayed clones on the immunomic array that yielded the best performance were sequenced for identification. Clones were amplified by PCR using T7 capsid forward and reverse primers (Novegan, Madison, WI, USA). After purification with MultiScreen-FB filter plate (Millipore) following the manufacturer's protocol, PCR products were sequenced using T7 capsid forward primer. DNA sequences and potential protein sequences were aligned using the NCBI BLAST program.
Coupling of phage epitopes to luminex beads
To reduce background, phage clones were purified twice with PEG 8000 to remove bacterial proteins. Next, Luminex microspheres were covalently conjugated with T7-tagged monoclonal antibodies (Novagen, Madison, WI) following standard carbodiimide coupling protocol according to the manufacturer's instructions. Purified phage clones were then individually incubated with T7 monoclonal antibody coupled beads for 1 h. After affinity purification, the beads were washed to remove unbounded phages.
Bead-based immunoassay
Individual beads carrying distinct phage epitopes were incubated with diluted serum samples for 1hr followed by washing. Then, a second antibody directly conjugated to the phycoerythrin fluorophore was used to quantify the amount of autoantibody bound to the tumor antigens displayed by the phages. Reporter fluorescence of the beads was determined with the Luminex analyzer and expressed as median fluorescence intensity. To calculate epitope-specific reactivity, the median fluorescence intensity of negative-control phage was used for normalization.
Meta-analysis
Using the Oncomine database (Oncomine, Compendia Bioscience, Ann Arbor, MI, USA), a meta-analysis of gene expression levels was conducted for each of the six in-frame proteins identified via immunomics. Each gene was evaluated in SCCHN versus normal and a meta-analysis was conducted using those studies. The studies were dichotomized to a zero and one scale based on significance at the five percent level, with significant studies assigned a value of one and insignificant studies the value of zero. The full set of results from this procedure was then subjected to a one-sample t-test against an expected value of 0.05.
Cell culture SCCHN cell lines were cultured as described previously. 39 All UM-SCC cell lines and OSCC3 were provided by T. Carey and P. Polverini (University of Michigan). Cell lines were genotyped by the Sequencing Core at the University of Michigan before all studies. Primary oral keratinocytes (ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured according to the manufacturer's instructions. NIH 3T3 cells were cultured in DMEM containing 5% calf serum. qPCR Quantitative real-time PCR was done with Power SYBR Green Master Mix on an Applied Biosystems 7600HT real-time PCR machine (Applied Biosystems, Foster City, CA, USA). cDNA was synthesized from total RNA isolated using SuperScript III (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Data were analyzed by relative quantification method with normalization to GAPDH and then relative to normal keratinocytes. The forward and reverse primers for L23 were 5 0 -AAAACCTGTATATCATCTCCGTGAA-3 0 and 5 0 -ACCACTGCTGGATGTACCTTTT-3 0 , respectively. Each sample was run in triplicate.
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Immunoblot analysis
Cells were lysed using 1% NP40 lysis buffer. Immunoblots were performed as described previously. 40 The primary antibodies used were: L23 (Everest Biotech, Oxfordshire, UK), GAPDH (Millipore) and Actin (BD Biosciences, Franklin Lakes, NJ, USA). Secondary antibodies were horseradish peroxidase-conjugated anti-goat or anti-mouse (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Immunoreactive proteins were visualized by SuperSignal West Pico Chemiluminescent system (Pierce, Pittsburgh, PA, USA). Signal intensity was quantified using ImageJ software (http://rsbweb.nih.gov/ij/).
Immunohistochemistry
Immunostaining on formalin-fixed, paraffin-embedded tissue and scoring of staining intensity was performed as described 41 on a SCCHN tissue microarray provided US Biomax (Rockville, MD, USA). The L23 antibody for immunohistochemical studies was from Sigma-Aldrich (St Louis, MO, USA). Mouse IgG was used instead of the primary antibody as a negative control.
Tumors obtained from in vivo experiments were sectioned and immunostained with L23 (Sigma-Aldrich), cytokeratin (Millipore) and PCNA (Cell Signaling, Danvers, MA, USA). Quantification of PCNA staining was done by counting the number of PCNA-positive cells in a total of 100 cells in three independent fields of each slide representing each tumor.
For analysis of TMA data, interpretation and scoring were performed by a board certified pathologist as described. 42 Multivariate analysis of L23 activity was based on the proportional odds ordinal regression model. The analysis had proportion in the nucleus as the primary response variable, categorized as none, low, medium and high. Explanatory variables included cancer diagnosis (binary), TNM stage (ordinal, four categories), grade differentiation (ordinal, three categories), age (15-82) and gender (binary). Models were fit by maximizing the likelihood. Forward and stepwise variable selection procedures and the likelihood ratio test were used to select the best model for the data and test statistical hypotheses.
Cell transfection and cell transduction with viral vectors
To downregulate L23 expression, OSCC3 and UM-SCC-22B cells were transfected with L23 siRNA (Dharmacon, Lafayette, CO, USA) using oligofectamine (Invitrogen). Non Target siRNA was used as a negative control. For stable downregulation of L23, UM-SCC-22B cells were transduced with lentiviral particles of L23 short hairpin RNA or shControl (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and selected with 50 mg/ ml of puromycin. After selection, cells were maintained at 20 mg/ml of puromycin. For overexpression of L23, SCC-11A cells were transfected with pcDNA-L23, (generous gift from Hua Lu, Oregon Health and Science University) or pcDNA (Invitrogen) using the Nucleofector-II system (Lonza, Allendale, NJ, USA). A mixed clonal population was selected using Geneticin (G418) at 10 mg/ml.
Proliferation assay
Cell growth was assessed by seeding cells at equal densities (B2 Â 10 4 ) in a 24-well plate. The number of viable, nonviable and total number of cells was determined by the Countess assay system using trypan blue (Invitrogen). Any P-value, calculated using the student's t-test, o0.05 was significant.
Invasion assay
Cell invasion was assessed 48 h after transfection using the modified Boyden chamber assay with Transwell inserts (Corning, Lowell, MA, USA) coated with Matrigel (BD Biosciences), as described. 39 Control inserts, not coated with matrigel, were used as a control for migration. Invasion was normalized with respect to migration according to the manufacturer's instructions. Any P-value, calculated using the student's t-test, o0.05 was significant.
Apoptosis
Apoptosis was measured using flow cytometry as well as TUNEL. For Flow cytometry cells were double stained with FITC-labeled Annexin V and propidium iodide using the FITC Annexin V Apoptosis Detection system (BD Biosciences) according to the manufacturer's instructions and analyzed via flow cytometry by the University of Michigan Flow Cytometry Core. The percent of total cells that stained positive for apoptosis was then quantified. For the TUNEL assay nicks in DNA were labeled with the DeadEnd Fluorometric TUNEL kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Cells were imaged on an Olympus BX-51 microscope (Olympus, Center Valley, PA, USA) at the Microscopy and Image Analysis Core at the University of Michigan. The percent of total cells that were positive for FITC fluorescence were quantified from six fields at Â 100 magnification. TUNEL was also performed on tissue sections obtained from in vivo studies according to manufacturer's instructions. The percent of 100 cells that were positive for FITC fluorescence were quantified from three fields at Â 40, of each individual tumor. A P-value of o0.05 was significant.
Focus forming assay NIH 3T3 cells were transfected with L23 or pcDNA using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Approximately 2e 5 cells were seeded on a 60-mm dish in triplicate, cultured for 7-14 days and fixed with 20% methanol:acetic acid (3:1) for 5 min at room temperature. After washing, the cells were stained with 0.2% crystal violet prepared in 70% ethanol. The average number of foci per plate was quantified and a P-value of o0.05 was significant.
In vivo studies
The effects of L23 on tumor growth was assessed using the athymic nude mice model, as described previously. 39, 43 UM-SCC-22B cells (1 Â 10 6 ) stably transduced with shL23 or shControl were injected s.c. in mice. A linear mixed effects statistical model was used to analyze the data. Random mouse-specific intercept term was included to adjust for tumor size measurements made on xenografts in the same mouse. Model-based Wald tests were used and a P-value o0.05 were significant.
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